We can’t show the full text here under this license. Use the link below to read it at the source.
Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis
Gut safety of semaglutide and tirzepatide compared to placebo in obese people without diabetes
AI simplified
Abstract
Overall GI adverse events were 1.86 times higher with both semaglutide and tirzepatide compared to placebo.
- Tirzepatide is associated with a greater risk of gastrointestinal adverse events than semaglutide, with a risk ratio of 2.94.
- Semaglutide increases the risk of gallbladder-related disorders, particularly cholelithiasis, by over 2.6 times.
- Tirzepatide does not show a significant biliary risk.
- Neither semaglutide nor tirzepatide significantly increases the risk of hepatic or pancreatic adverse events.
- Most gastrointestinal adverse events reported are mild.
AI simplified